GRAIL, Inc. (GRAL)
NASDAQ: GRAL · Real-Time Price · USD
77.50
+1.61 (2.12%)
Sep 16, 2026, 11:48 AM EDT - Market open
GRAIL Employees
GRAIL had 910 employees as of December 31, 2025. The number of employees decreased by 90 or -9.00% compared to the previous year.
Employees
910
Change (1Y)
-90
Growth (1Y)
-9.00%
Revenue / Employee
$181,608
Profits / Employee
-$430,315
Market Cap
3.46B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 910 | -90 | -9.00% |
| Dec 31, 2024 | 1,000 | -360 | -26.47% |
| Sep 30, 2024 | 1,170 | -190 | -13.97% |
| Dec 31, 2023 | 1,360 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| RadNet | 9,276 |
| Qiagen | 5,700 |
| Sotera Health Company | 3,000 |
| NeoGenomics | 2,500 |
| GeneDx Holdings | 1,300 |
| CareDx | 765 |
| Veracyte | 755 |
| Adaptive Biotechnologies | 624 |
GRAL News
- 2 days ago - GRAIL Transcript: Morgan Stanley 24th Annual Global Healthcare Conference - Transcripts
- 7 days ago - Grail initiated with a Buy at UBS - TheFly
- 12 days ago - GRAIL Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - PRNewsWire
- 15 days ago - GRAIL to Present at Morgan Stanley's 24th Annual Global Healthcare Conference - PRNewsWire
- 5 weeks ago - GRAIL Transcript: Canaccord Genuity's 46th Annual Growth Conference - Transcripts
- 5 weeks ago - US FDA to hold advisory meeting to review Grail's multi-cancer test - Reuters
- 5 weeks ago - Grail announces FDA advisory committee meeting to review Galleri test PMA - TheFly
- 5 weeks ago - GRAIL Announces FDA Advisory Committee Meeting to Review Premarket Approval Application for the Galleri® Multi-Cancer Early Detection Test - PRNewsWire